MIR25

Summary

MIR25 (microRNA 25, HGNC:31609) is a microRNA gene on chromosome 7q22.1.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 407014 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31609
Approved symbol	MIR25
Name	microRNA 25
Location	7q22.1
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-25
Ensembl gene	ENSG00000207547
Ensembl biotype	miRNA
OMIM	612150
Entrez	407014
RNAcentral	URS00000C85B2 — miRNA, 84 nt, 51 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000384816

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000384816 — 1 exons

Exon	Start	End
ENSE00001499823	100093560	100093643

Expression profiles

Bgee: expression breadth ubiquitous, 120 present calls, max score 95.85.

Top tissues by expression

120 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	95.85	gold quality
endometrium	UBERON:0001295	95.16	gold quality
bone marrow	UBERON:0002371	94.70	gold quality
vermiform appendix	UBERON:0001154	92.98	gold quality
mucosa of transverse colon	UBERON:0004991	92.43	gold quality
duodenum	UBERON:0002114	90.84	gold quality
spleen	UBERON:0002106	90.36	gold quality
skeletal muscle tissue	UBERON:0001134	89.86	gold quality
right uterine tube	UBERON:0001302	89.81	gold quality
small intestine	UBERON:0002108	89.16	gold quality
small intestine Peyer’s patch	UBERON:0003454	89.02	gold quality
body of stomach	UBERON:0001161	87.74	gold quality
tonsil	UBERON:0002372	87.49	gold quality
stomach	UBERON:0000945	87.26	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.91	gold quality
transverse colon	UBERON:0001157	86.68	gold quality
adrenal tissue	UBERON:0018303	86.53	gold quality
placenta	UBERON:0001987	86.51	gold quality
right hemisphere of cerebellum	UBERON:0014890	86.06	gold quality
right adrenal gland	UBERON:0001233	85.81	gold quality
body of pancreas	UBERON:0001150	85.66	gold quality
right adrenal gland cortex	UBERON:0035827	85.62	gold quality
intestine	UBERON:0000160	85.15	gold quality
adrenal gland	UBERON:0002369	84.62	gold quality
left adrenal gland cortex	UBERON:0035825	84.57	gold quality
cerebellar hemisphere	UBERON:0002245	84.54	gold quality
left adrenal gland	UBERON:0001234	84.36	gold quality
uterus	UBERON:0000995	84.33	gold quality
fundus of stomach	UBERON:0001160	83.80	gold quality
colon	UBERON:0001155	83.73	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.82

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• Suggest that the miR-106b-25 cluster is involved in E2F1 posttranscriptional regulation and may play a key role in the development of TGFbeta resistance in gastric cancer. (PMID:18328430)
• Knock-down studies for the miR-106b-25 cluster, which includes miR-106b, miR-93 and miR-25, showed that the expression of the cluster is necessary for cell proliferation and for anchorage-independent growth. (PMID:19486339)
• inhibition of miR-25 in cytokine-stimulated ASM cells up-regulates KLF4 expression via a post-transcriptional mechanism. (PMID:19541842)
• demonstrated that the intronic miR-106b~25 cluster cooperates with its host gene MCM7 in cellular transformation both in vitro and in vivo, so that the concomitant overexpression of MCM7 and the miRNA cluster triggers prostatic intraepithelial neoplasia (PMID:20388916)
• The deregulation of this miRNA cluster(Mir106b and Mir-25) may alter Treg cells activity in course of MS, by altering TGF-beta biological functions. (PMID:20637509)
• In addition to miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d. (PMID:20935678)
• miR-25 target DR4 provides a mechanism by which miR-25 contributes to evasion of TRAIL-induced cholangiocarcinoma apoptosis (PMID:21953056)
• miR-25 directly regulates apoptosis by targeting Bim in ovarian cancer. (PMID:22076535)
• results define miR-25 and -32 as positive regulators of p53, underscoring their role in tumorigenesis in glioblastoma (PMID:22431589)
• These results, for the first time, demonstrate that miR-25 promotes esophageal squamous cell carcinoma cell migration and invasion by suppressing CDH1 expression. (PMID:22450326)
• miR-25 associates to residual beta-cell function and glycaemic control during disease progression (PMID:22829805)
• MIR25 targets the mitochondrial calcium uniporter (MCU) and its overexpression in HeLa cells drastically reduces MCU levels and mitochondrial Ca(2+) uptake, while leaving other mitochondrial parameters and cytosolic Ca(2+) signals unaffected. (PMID:23246404)
• MiR-25 may function as a tumor suppressor by targeting Smad7 in colon cancer. (PMID:23435373)
• Data indicate that miR-106b-25 cluster (miR-106b, miR-93 and miR-25) targets the 3’UTR of the beta-TRCP2 transcript and increases the expression of Snail. (PMID:23611780)
• Data indicate that miR-17-92 families miR-19b, miR-20a, miR-25 and miR-92a might implicate in apoptosis induction in the some of the cells and conditions. (PMID:23681423)
• MiR-25-3p inhibited the proliferation of tongue squamous cell carcinoma cells and regulated cell cycle-related protein expression. (PMID:23827155)
• our work suggests that miR-25-mediated down-regulation of DSC2 promotes esophageal squamous cell carcinoma cell aggressiveness through redistributing adherens junctions and activating beta-catenin signalling (PMID:23836524)
• miR-25 might promote gastric cancer cell growth and motility partially by targeting RECK. (PMID:24078004)
• miR-25 expression is increased in colorectal cancer and may have a role in tumor progression (PMID:24293092)
• miR-25, miR-223, and miR-375 were abnormally expressed in ESCC tissues and sera. Serum miR-223 and miR-375 are potential prognostic biomarkers for ESCC. (PMID:24390317)
• Our data suggests that the overexpression of miR-25 in hepatocellular carcinoma tissues is of predictive value on poor prognosis (PMID:24593846)
• Tissue miR-25 expression may be associated with tumor progression and have prognostic implications in female lung Adenocarcinoma patients. (PMID:24606441)
• Genetic variation in MIR25 is associated with gastric cancer. (PMID:24643999)
• increased expression of endogenous miR-25 contributes to declining cardiac function during heart failure and suggest that it might be targeted therapeutically to restore function (PMID:24670661)
• The increased expression of miR-25 is closely related to poor prognosis of epithelial ovarian cancer (PMID:24696291)
• The protein expression of p27, a cellcycle inhibitor, is negatively regulated by miR25. (PMID:24859599)
• The levels of expression of 25 miRNA remained high and ten of these miRNA showed different expression from that at day 0. (PMID:24960647)
• miR-25 promotes GC progression by directly downregulating TOB1 expression, and may be a noninvasive biomarker for the prognosis of GC patients. (PMID:25043310)
• abnormal upregulation of ANGPTL2 in colorectal cancer is associated with miR-25 downregulation (PMID:25174582)
• miR-25 negatively regulated LATS2 expression and promoted OC cell growth and motility. (PMID:25179841)
• The expression of the miR-25/93/106b family may be regulated through mechanisms distinct from its host gene, MCM7 (PMID:25243570)
• Logistic regression analysis demonstrated that miR-16 and miR-25 were independent factors for intracranial aneurysm occurrence. (PMID:25249297)
• MiR-25, by targeting CDC42, is an important regulator in NSCLC. (PMID:25432132)
• miR-25 reduced both wild-type and polyQ-expanded mutant ataxin-3 protein levels by interacting with the 3’UTR of ATXN3 mRNA (PMID:25451224)
• Our study shows miR-25 is overexpressed in small cell lung cancer and acting as oncogenic regulator by regulating cyclin E2. (PMID:25550809)
• MiR-25 promotes cell proliferation by targeting RECK in human cervical carcinoma. (PMID:25575057)
• By applying loss-and-gain function analysis in NSCLC cell lines, we demonstrated that miR-25-BTG2 axis could directly regulated BTG2 expression and affect radiotherapy sensitivity of NSCLC cells. (PMID:25576360)
• High MIRN25 expression is associated with esophageal adenocarcinoma. (PMID:25784377)
• miR-25/miR-107-LATS2 axis might play an important role in proliferation and invasion of the gastric cancer cells (PMID:25824045)
• our observations suggest that miR-25 is a key regulator of invasiveness in human prostate cancer through its direct interactions with av- and a6-integrin expression (PMID:25858144)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	mir25	ENSDARG00000101889
mus_musculus	Mir25	ENSMUSG00000065394

Paralogs (2): MIR92A1 (ENSG00000283705), MIR92A2 (ENSG00000284538)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.